Kai Lin

发表

Mechanism of Resistance of Hepatitis C Virus Replicons to Structurally Distinct Cyclophilin Inhibitors

X. Puyang, Shejin Zhu, D. Poulin, 2010, Antimicrobial Agents and Chemotherapy.

Inhibition of cyclophilins alters lipid trafficking and blocks hepatitis C virus secretion

L. Anderson, Kai Lin, T. Compton, 2011, Virology Journal.

Anti-HCV drugs in the pipeline.

Qingsong Liu, Priscilla L. Yang, Kai Lin, 2011, Current opinion in virology.

Development of novel antiviral therapies for hepatitis C virus

Kai Lin, 2010, Virologica Sinica.

Design and synthesis of lactam-thiophene carboxylic acids as potent hepatitis C virus polymerase inhibitors.

Christopher T. Jones, K. Hoffmaster, Mitsunori Kato, 2014, Bioorganic & medicinal chemistry letters.

Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

A. Kwong, B. G. Rao, P. Chaturvedi, 2006, Antimicrobial Agents and Chemotherapy.

NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon

N. Ryder, Sue Ma, Kai Lin, 2006, Antimicrobial Agents and Chemotherapy.

Development of a Flow Cytometry Live Cell Assay for the Screening of Inhibitors of Hepatitis C Virus (HCV) Replication

M. Gregory, B. Wilkinson, P. Gallay, 2012, The open virology journal.

Preclinical and Clinical Resistance Profile of EDP-239, a Novel Hepatitis C Virus NS5A Inhibitor

C. M. Owens, Christopher T. Jones, Kai Lin, 2016, Antimicrobial Agents and Chemotherapy.

Protein-primed RNA synthesis in SARS-CoVs and structural basis for inhibition by AT-527

E. Decroly, B. Canard, J. Vasseur, 2021, bioRxiv.

Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics.

M. Murcko, Chao Lin, R. Perni, 2007, Bioorganic & medicinal chemistry letters.

Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 proline variants.

M. Murcko, K. Wilson, B. G. Rao, 2004, Bioorganic & medicinal chemistry letters.

Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.

B. G. Rao, Chao Lin, S. Harbeson, 2004, Bioorganic & medicinal chemistry letters.

Combinations of Cyclophilin Inhibitor NIM811 with Hepatitis C Virus NS3-4A Protease or NS5B Polymerase Inhibitors Enhance Antiviral Activity and Suppress the Emergence of Resistance

Sue Ma, Kai Lin, T. Compton, 2008, Antimicrobial Agents and Chemotherapy.

Evaluation of AT-752, a Double Prodrug of a Guanosine Nucleotide Analog with In Vitro and In Vivo Activity against Dengue and Other Flaviviruses

B. Canard, P. la Colla, J. Sommadossi, 2021, Antimicrobial agents and chemotherapy.

Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV

Kai Lin, 2011 .

EDP-938, a novel nucleoprotein inhibitor of respiratory syncytial virus, demonstrates potent antiviral activities in vitro and in a non-human primate model

B. Shook, S. Noton, R. Fearns, 2021, PLoS pathogens.

Beat Interferon Virus Alone or in Combination with Alpha Potent In Vitro Activity against Hepatitis C NIM 811 , a Cyclophilin Inhibitor , Exhibits

N. Ryder, Sue Ma, Kai Lin, 2006 .

A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase

E. Decroly, A. Delpal, B. Canard, 2021, Nature Communications.

LB6. EDP-938, a Novel RSV N-Inhibitor, Administered Once or Twice Daily Was Safe and Demonstrated Robust Antiviral and Clinical Efficacy in a Healthy Volunteer Challenge Study

E. Coakley, Kai Lin, K. Larson, 2019, Open Forum Infectious Diseases.

Curing a viral infection by targeting the host: The example of cyclophilin inhibitors

P. Gallay, Kai Lin, 2013, Antiviral Research.

Combination of a Hepatitis C Virus NS3-NS4A Protease Inhibitor and Alpha Interferon Synergistically Inhibits Viral RNA Replication and Facilitates Viral RNA Clearance in Replicon Cells

Ann D. Kwong, A. Kwong, Chao Lin, 2004, Antimicrobial Agents and Chemotherapy.

Telbivudine Exhibits No Inhibitory Activity against HIV-1 Clinical Isolates In Vitro

E. Lam, T. Evans, Kai Lin, 2010, Antimicrobial Agents and Chemotherapy.

FRI-191-EDP-514, a novel HBV core inhibitor with potent antiviral activity both in vitro and in vivo

B. Goodwin, Kai Lin, Xiaowen Peng, 2019, Journal of Hepatology.

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

Ann D. Kwong, A. Kwong, Chao Lin, 2006, Antimicrobial Agents and Chemotherapy.

Multiple cyclophilins involved in different cellular pathways mediate HCV replication.

T. Bouwmeester, M. Schirle, C. Mickanin, 2010, Virology.

NIM811, A Cyclophilin Inhibitor, and NM107, An HCV Polymerase Inhibitor, Synergistically Inhibits HCV Replication and Suppresses the Emergence of Resistance In Vitro

Sue Ma, Kai Lin, T. Compton, 2007 .

In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061*

A. Kwong, B. G. Rao, J. Fulghum, 2005, Journal of Biological Chemistry.

Multiple Mutations in Hepatitis C Virus NS5A Domain II Are Required To Confer a Significant Level of Resistance to Alisporivir

M. Gregory, B. Wilkinson, P. Gallay, 2012, Antimicrobial Agents and Chemotherapy.

Inhibition of Dengue Virus Polymerase by Blocking of the RNA Tunnel

P. Niyomrattanakit, Yen-Liang Chen, P. Shi, 2010, Journal of Virology.

Profile of alisporivir and its potential in the treatment of hepatitis C

P. Gallay, Kai Lin, 2013, Drug design, development and therapy.

Resistance mutations against HCV protease inhibitors and antiviral drug design.

Luqing Shang, Zheng Yin, Kai Lin, 2014, Current pharmaceutical design.

In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061

John R Fulghum, A. Kwong, B. G. Rao, 2004, Journal of Biological Chemistry.

Correlation between NS5A Dimerization and Hepatitis C Virus Replication*

C. Cameron, P. Gallay, Suresh D. Sharma, 2012, The Journal of Biological Chemistry.

HCV NS5A and IRF9 compete for CypA binding.

J. Hiscott, A. Sluder, P. Gallay, 2013, Journal of hepatology.

Class III Phosphatidylinositol 4-Kinase Alpha and Beta Are Novel Host Factor Regulators of Hepatitis C Virus Replication

John A. Tallarico, T. Bouwmeester, M. Schirle, 2009, Journal of Virology.

Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239

C. M. Owens, S. Zeuzem, P. Buggisch, 2016, Antimicrobial Agents and Chemotherapy.

AT-752, a double prodrug of a guanosine nucleotide analog, inhibits yellow fever virus in a hamster model

J. Sommadossi, Kai Lin, J. Julander, 2021, bioRxiv.

Recent Advances in Developing Antiviral Therapies for Respiratory Syncytial Virus

B. Shook, Kai Lin, 2017, Topics in Current Chemistry.

AT-752 targets multiple sites and activities on the Dengue virus replication enzyme NS5.

Priscila Sutto-Ortiz, E. Decroly, P. Shi, 2023, Antiviral research.

Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG.

Tara L. Kieffer, R. Schooley, C. Petropoulos, 2011, Gastroenterology.

and Hepatitis C Virus Replication Correlation between NS5A Dimerization RNA

C. Cameron, P. Gallay, Suresh D. Sharma, 2014 .

[608] NIM811, A CYCLOPHILIN INHIBITOR, AND NM107, AN HCV POLYMERASE INHIBITOR, SYNERGISTICALLY INHIBITS HCV REPLICATION AND SUPPRESSES THE EMERGENCE OF RESISTANCE IN VITRO

Sue Ma, Kai Lin, T. Compton, 2007 .

ALISPORIVIR - A HOST-TARGETING ANTIVIRAL, PROVIDES LOW VIRAL BREAKTHROUGH RATE AND HIGH BARRIER TO RESISTANCE IN HCV GENOTYPE 1 TREATMENT-NAiVE PATIENTS IN THE PHASE IIB ESSENTIAL STUDY

Christopher T. Jones, A. Vandamme, J. Snoeck, 2011 .

Anti-Hepatitis C Virus Activity and Toxicity of Type III Phosphatidylinositol-4-Kinase Beta Inhibitors

P. Raman, R. Colvin, R. Tommasi, 2012, Antimicrobial Agents and Chemotherapy.